Artiria Medical secures USD 6 million to advance stroke treatment technology in Europe and US
scroll south
Following positive initial results and FDA approval, the Swiss MedTech company Artiria Medical — developing next-generation neuro-interventional products for stroke and aneurysms — closes a Series A2 round of USD 6M and secures USD 0.6M Fit Tech Growth loan to complete clinical trials of its stroke treatment technology in both Europe and the United States.
Artiria’s leading product is a novel real-time deflectable guidewire that enables neurointerventional surgeons to access the diseased site faster. The product has already been used in humans and treated its first patients in the third quarter of 2023 while gaining significant traction from physicians in the neurointerventional setting.
Artiria's Co-Founders: COO Marc Boers and CEO Guillaume Petit-Pierre
This Series A2 investment round, led by 4FOX Ventures, was joined by the Wyss Center for Bio and Neuroengineering, and existing investors including Verve Ventures, the Zürcher Kantonalbank, the NEST pension fund, and business angels.
Artiria participated in Venture Leaders Medtech in 2023 and Venture Leaders Life Sciences in 2018, was ranked among the TOP 100 Swiss Startups in 2020, 2021, and 2023, and won the last stage of Venture Kick in 2019.
Artiria's team: Loïc Sottas (R&D Project Leader), Benoît Dubath (R&D Engineer), Guillaume Petit-Pierre (CEO & Co-Founder), Julien Cevey (Quality Manager), Marc Boers (COO & Co-Founder), and Hadrien Michaud (R&D Manager).
Artiria Medical SA: A new standard of care to fight stroke and save lives.
Artiria Medical is revolutionising neurovascular healthcare with cutting-edge minimally invasive medical technologies. Our first product, an innovative FDA-cleared wire with a micro-articulated seekin... Read more
